VivoSeq
Other

Cognitive Disorder

20

Pipeline Programs↗

5

Active Trials↗

11

Companies Involved↗

Cognitive Disorder is an emerging landscape with 20 programs across 11 companies. The most active players are Azurity Pharmaceuticals, Sebela Pharmaceuticals Development LLC, AbbVie. 4 therapies are approved with 2 more in late-stage development.

Intelligence

Pipeline Metrics

Competitive Density

47/100

Pipeline Velocity

6/100

Mech. Concentration

17/100

Completion Rate

80/100

Attrition Rate

14/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

A

Azurity Pharmaceuticals

1 program

Phase 1S

Sebela Pharmaceuticals Development LLC

1 program

Phase 2AbbVie logo

AbbVie

1 program

Phase 3Novo Nordisk logo

Novo Nordisk

1 program

ApprovedGilead logo

Gilead

1 program

ApprovedP

Pfizer's Upjohn has merged with Mylan to form Viatris Inc.

2 programs

Approved

Pipeline

Programs by Phase

Analysis

Modality Breakdown

96%

Small molecule

23 of 24 classified programs — the dominant modality here.

4%ALL OTHERSPeptide14%

Small molecule leads; the ring shows all 24 classified programs, each share of the total. Modality classified for 100% of 30 pipeline programs.

Analysis

Trial Status

22

clinical trials

Completed12 · 55%
Recruiting4 · 18%
Terminated3 · 14%
Unknown status2 · 9%
Not yet recruiting1 · 5%

Clinical Trials

Trial Activity

22 trials

Single-center Prospective Longitudinal Study of Taste in Patients With Cognitive Disorders at Different Stages of Severity (Isolated Cognitive Complaint, Minor or Major Neurocognitive Alzheimer-type Disorders) by Analysis of Gustatory Evoked Potentials
Recruiting·—·N/A·NCT05888961·72 enrolled
Anesthesia and Perioperative Neurocognitive Disorders in the Elderly Patients Undergoing Hip Fracture Surgery Platform Trial (ANDES Platform Trial)
Recruiting·SSecond Affiliated Hospital of Wenzhou Medical University·N/A·NCT06452147·1,860 enrolled
Efficacy and Safety of Oral Midazolam Used for the Delivery of Care in Elderly Patient With Neurocognitive Disorders and Refusing Care.
Recruiting·UUniversity Hospital, Grenoble·Phase 2·NCT06638710·30 enrolled
A Pilot, Multicentre, Controlled, Open-label Study Evaluating 24 Months of Lithium Carbonate Treatment in Patients With TBR1-related Neurocognitive Disorder
Recruiting·—·Phase 1/2·NCT06776848·12 enrolled
Efficacy of EMONO as an add-on Therapy to Conventional Antidepressants for the Treatment of Depressive Symptoms in Nursing-home Residents With Neurocognitive Disorders: a Randomized Controlled Trial-
Not yet recruiting·UUniversity Hospital, Tours·Phase 2·NCT06382389·96 enrolled
EGb 761® (Tanakan®) Effectiveness in the Treatment of Patients of Middle Age and Younger With Psycho-emotional Symptoms, Added to Cognitive Disorders
Completed·Ipsen logoIpsen·N/A·NCT02321475·54 enrolled
Clinical Trial of Efficacy and Safety of MMH-MAP in the Treatment of Cognitive Disorders
Completed·MMateria Medica Holding·Phase 3·NCT04295681·246 enrolled
Effects of Losartan and Antiretroviral Regimen Containing Raltegravir in Fibrosis Inflammation Mediators, Cardiovascular Risk and Neurocognitive Disorders in HIV Infected Patients Previously Effectively Treated
Completed·—·Phase 4·NCT01529749·48 enrolled
Study on Efficacy and Safety of Divaza in Patients With Chronic Cerebral Ischemia and Cognitive Disorders
Completed·MMateria Medica Holding·N/A·NCT04370028·2,583 enrolled
Prospective Monocentric Study of Taste in Patients With Minor or Major Cognitive Disorders Such as Alzheimer's, Through the Analysis of Gustatory Evoked Potentials.
Completed·—·N/A·NCT04860414·45 enrolled
Study on Cognitive Disorders of Multiple Sclerosis
Completed·UUniversity Hospital, Caen·Phase 3·NCT01074619·90 enrolled
Downmodulating Monocyte Activation for HIV-1 Associated Neurocognitive Disorders (HAND)
Completed·UUniversity of Pennsylvania·Phase 4·NCT01600170·11 enrolled
Methylene Blue and Postoperative Neurocognitive Disorders
Completed·FFudan University·N/A·NCT04529265·314 enrolled
The Impact of Dementia and Neurocognitive Disorders on Hypertension Treatment in the Elderly
Completed·—·N/A·NCT05845736·353 enrolled
Falls With Fracture : Role of Cognitive Disorders and Comparison With Bone Fragility
Completed·UUniversity Hospital, Caen·N/A·NCT02292316·218 enrolled
Page 1 of 2

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)